Compare DexCom, Inc. (DXCM) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs KraneShares Electric Vehicles and Future Mobility — how do they compare? DexCom, Inc. trades at $90.52 (market cap $33.79B), while KraneShares Electric Vehicles and Future Mobility trades at $30.99. The key difference: DexCom, Inc. is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| DXCM | KARS | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Sector/Thematic |
52-Week High | $89.53 | $38.01 |
52-Week Low | $54.84 | $25.59 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
KARS trades at $30.99, down 0.42% on the day, with a bullish technical signal driven by moving averages and oscillators. The stock faces resistance near $31-$32, while support lies at $30-$29. Recent news highlights global EV sales growth, with China targeting 30% NEV fleet by 2030 and Europe seeing demand surges from high fuel prices, though U.S. adoption lags.
The outlook for KARS is supported by EV industry tailwinds, but risks include competitive pressures from Chinese automakers and regulatory delays. Analyst sentiment is mixed, with technical indicators suggesting near-term consolidation. Institutional interest may hinge on sustained EV adoption trends and execution against growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
